

USSN: 10/632,742


Ref. No. PC 27169

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:


Listing of Claims:

1. (Currently Amended) A compound of formula I

**I**

or a pharmaceutically acceptable salt thereof wherein:

A is



X<sup>1</sup> and Y<sup>1</sup> together form the group -C(=O)N(R<sup>5</sup>)- wherein X<sup>1</sup> is NR<sup>5</sup> and Y<sup>1</sup> is C(=O)  
Z<sup>1</sup> is

- (a) NHC(=O)R<sup>1</sup>, or
- (b) NHC(=S)R<sup>1</sup>,
- (c) ~~NH het<sup>1</sup>~~,
- (d) ~~O het<sup>1</sup>~~,
- (e) ~~S het<sup>1</sup>, or~~
- (f) ~~het<sup>2</sup>~~;

R<sup>1</sup> is

- (a) NH<sub>2</sub>,
- (b) NHC<sub>1-4</sub>alkyl,
- (c) C<sub>1-4</sub>alkyl,
- (d) C<sub>2-4</sub>alkenyl,
- (e) -CH<sub>2</sub>C(=O)C<sub>1-4</sub>alkyl,
- (f) OC<sub>1-4</sub>alkyl,

USSN: 10/632,742

Ref. No. PC 27169

- (g)  $\text{SC}_{1-4}\text{alkyl}$ , or
- (h)  $\text{C}_{3-6}\text{cycloalkyl}$ ;

Each X, Y, and Z is independently selected from

- (a) H,
- (b) Cl,
- (c) F, or
- (d)  $\text{CH}_3$

 $R^4$  is



- (a) H,
- (b)  $\text{C}_{1-4}\text{alkyl}$ ,
- (c)  $\text{OC}_{1-4}\text{alkyl}$ ,
- (d)  $\text{SC}_{1-4}\text{alkyl}$ , or
- (e)  $\text{NHC}_{1-4}\text{alkyl}$ ;

 $R^5$  is

- (a) H,
- (b)  $\text{C}_{1-4}\text{alkyl}$ , or
- (c)  $-(\text{CH}_2)_n-\text{W}_1-(\text{CH}_2)_n-Z^3$ ;

 $W_1$  is

- (a)  $-\text{CH}_2-$ ,
- (b)  $-\text{CH}=\text{CH}-$ ,
- (c)  $-\text{C}\equiv\text{C}-$ , or

 $Z^3$  is $W_2$  is

- (a)  $-\text{O}-$ ,

USSN: 10/632,742

Ref. No. PC 27169

(b)  $-N(R_{25})-$ , or(c)  $-C(=O)-N(R_{25})-$ , wherein either the carbon or the nitrogen atom of the amide may be bound to a carbon atom of the phenyl ring of  $Z^3$ ; $R_{22}$  is  $(CH_2)_tNR_{23}R_{24}$ , H, halo,  $C_{1-4}$ alkyl,  $-CN$ ,  $-OH$ ,  $-O-C_{1-4}$ alkyl,  $-S(O)_tC_{1-4}$ alkyl, and  $-C(=O)NH_2$  $R_{23}$  is H or  $C_{1-4}$ alkyl; $R_{24}$  is H,  $C_{1-4}$ alkyl,  $-S(O)_2-C_{1-4}$ alkyl,  $-C(=O)-C_{1-4}$ alkyl,  $-C(=NH)-NH_2$ ,  $-C(=O)-C(HR_{26})-NR_{27}R_{28}$ ; $R_{25}$  is H or  $C_{1-4}$ alkyl; $R_{26}$  is H,  $C_{1-4}$ alkyl which can be optionally substituted by  $-OH$ ,  $-NH_2$ ,  $-NH-C(=NH)-NH_2$ ,  $-SH$ ,  $-SCH_3$ ,  $-COOH$ ,  $-C(O)NH_2$ , and phenyl which can be optionally substituted with  $-OH$ , imidazole, indole, or  $R_{26}$  and  $R_{27}$  together with the carbon atom to which  $R_{26}$  attaches and the nitrogen atom to which  $R_{27}$  attaches form a heterocycloalkyl; $R_{27}$  is H or  $C_{1-4}$ alkyl; $R_{28}$  is H,  $C_{1-4}$ alkyl,  $-S(O)_2-C_{1-4}$ alkyl,  $-C(=O)-C_{1-4}$ alkyl,  $-C(=NH)-NH_2$ ,  $-C(=O)-C(HR_{26})-NR_{27}R_{27}$  $t$  is 0, 1; $u$  is 0, 1, 2; $n$  is 1 or 2; and~~het<sup>1</sup> is a C-linked five (5) or six (6) membered heterocyclic ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen; het<sup>1</sup> being optionally substituted on one or more carbon atoms by 1-2 substituents selected from  $C_1-C_4$ alkyl, amino,  $C_1-C_4$ alkylamino,  $C_1-C_4$ alkyloxy, halogen,  $CN$ ,  $=O$ ,  $=S$ , and being optionally substituted with  $C_1-C_4$ alkyl;~~~~het<sup>2</sup> is a N-linked five (5) or six (6) membered heterocyclic ring having at least one nitrogen atom, and optionally having one oxygen or sulfur atom; het<sup>2</sup> being optionally substituted on one or more carbon atoms by 1-2 substituents selected from  $C_1-C_4$ alkyl, amino,  $C_1-C_4$ alkylamino,  $C_1-C_4$ alkyloxy, halogen,  $CN$ ,  $=O$ ,  $=S$ , and being optionally substituted with  $C_1-C_4$ alkyl;~~~~heterocycloalkyl is a four (5) or seven (7) membered saturated heterocyclic ring having 1-4 heteroatoms selected from the group consisting of oxygen, sulfur, and~~

USSN: 10/632,742

Ref. No. PC 27169

~~nitrogen; heterocycloalkyl being optionally substituted on one or more carbon atoms by 1-2 substituents selected from C<sub>1</sub>-C<sub>4</sub>alkyl, amino, C<sub>1</sub>-C<sub>4</sub>alkylamino, C<sub>1</sub>-C<sub>4</sub>alkyloxy, halogen -CN, =O, =S, and being optionally substituted with C<sub>1</sub>-C<sub>4</sub>alkyl;~~

~~at each occurrence, alkyl, alkenyl, or cycloalkyl is optionally substituted with 1-3 halo, -OH, -OC<sub>1</sub>-C<sub>4</sub>alkyl, and~~

~~Aryl refers to phenyl, biphenyl, or naphthyl, optionally substituted with halo, C<sub>1</sub>-C<sub>4</sub>alkyl, OH, OC<sub>1</sub>-C<sub>4</sub>alkyl, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NH(C<sub>1</sub>-C<sub>4</sub>alkyl), and S(O)<sub>n</sub>C<sub>1</sub>-C<sub>4</sub>alkyl.~~

2. (Canceled)

3. (Original) The compound of claim 1, wherein X is F.

4. (Original) The compound of claim 3, wherein Y is F.

5. (Original) The compound of claim 1, wherein Z<sup>1</sup> is -NH-C(O)R<sub>1</sub>.

6. (Original) The compound of claim 5, wherein R<sub>1</sub> is selected from C<sub>1</sub>-C<sub>4</sub>alkyl optionally substituted with 1-3 halo.

7. (Original) The compound of claim 6, wherein R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub>alkyl substituted with 1-2 halo.

8. (Original) The compound of claim 1, wherein Z<sup>1</sup> is -NH-C(S)R<sub>1</sub>.

9. (Original) The compound of claim 8, wherein R<sub>1</sub> is selected from C<sub>1</sub>-C<sub>4</sub>alkyl optionally substituted with 1-3 halo.

10. (Original) The compound of claim 9, wherein R<sub>1</sub> is C<sub>1</sub>-C<sub>4</sub>alkyl substituted with 1-2 halo.

11. (Original) The compound of claim 1, wherein Y<sup>1</sup> is -C(=O)- and X<sup>1</sup> is -N(R<sub>5</sub>)-.

USSN: 10/632,742

Ref. No. PC 27169

12. (Canceled)

13. (Original) A compound selected from the group consisting of

*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;

2,2-dichloro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;

2,2-difluoro-*N*-({(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

2,2-dichloro-*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide;

*N*-({(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroacetamide;

*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;

*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)propanamide;

2,2-dichloro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;

2,2-difluoro-*N*-({(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;

USSN: 10/632,742

Ref. No. PC 27169

2,2-difluoro-N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;  
((5S)-3-[4-(1-methyl-6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;  
N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;  
N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;  
2,2-difluoro-N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;  
N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;  
N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;  
N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide;  
N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;  
2,2-difluoro-N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;  
N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)propanamide; and  
N-((5S)-3-[4-(1-methyl-2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide.

14. (Original) A compound selected from the group consisting of

N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide; N-((5S)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;  
N-((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

USSN: 10/632,742

Ref. No. PC 27169

*N*-{(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;  
*N*-{(5*S*)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)propanamide;  
({(5*S*)-3-[4-(1-methyl-6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;  
*N*-{(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;  
*N*-{(5*S*)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;  
*N*-{(5*S*)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;  
*N*-{(5*S*)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)propanamide;  
*N*-{(5*S*)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;  
*N*-{(5*S*)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)propanamide; and  
*N*-{(5*S*)-3-[4-(1-methyl-2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide.

15. (Original) A compound selected from the group consisting of

2,2-dichloro-*N*-{(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;  
2,2-difluoro-*N*-{(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;  
2,2-difluoro-*N*-{(5*S*)-3-[3-fluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;  
2,2-dichloro-*N*-{(5*S*)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide;

USSN: 10/632,742

Ref. No. PC 27169

*N-((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide;*

*N-((5S)-3-[3,5-difluoro-4-(6-oxopiperidin-3-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroacetamide;*

*2,2-dichloro-N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)acetamide;*

*2,2-difluoro-N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;*

*2,2-difluoro-N-((5S)-2-oxo-3-[4-(6-oxopiperidin-3-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide;*

*2,2-difluoro-N-((5S)-3-[3-fluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)ethanethioamide;*

*N-((5S)-3-[3,5-difluoro-4-(2-oxopiperidin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)-2,2-difluoroethanethioamide; and*

*2,2-difluoro-N-((5S)-2-oxo-3-[4-(2-oxopiperidin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)ethanethioamide.*

16. (Canceled)

17. (Original) A method for the treatment of microbial infections in mammals comprising administration of an effective amount of compound of claim 1 to said mammal.

18. (Original) The method of claim 17 wherein said compound of claim 1 is administered to the mammal orally, parenterally, transdermally, or topically in a pharmaceutical composition.

19. (Original) The method of claim 18 wherein said compound is administered in an amount of from about 0.1 to about 100 mg/kg of body weight/day.

USSN: 10/632,742

Ref. No. PC 27169

20. (Original) The method of claim 18 wherein said compound is administered in an amount of from about 1 to about 50 mg/kg of body weight/day.

21. (Original) A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.